Diabetes as a Cause of Clinically Significant Functional Cobalamin Deficiency by Solomon, Lawrence R.
Diabetes as a Cause of Clinically
Signiﬁcant Functional Cobalamin
Deﬁciency
LAWRENCE R. SOLOMON, MD
OBJECTIVE—Functional cobalamin (Cbl) deﬁciency (i.e., high methylmalonic acid [MMA]
valuesdespitenormalserumCbllevels)iscommonintheelderlyandassociatedwithneuropathy
and anemia. Because diabetes is also common in the elderly and diabetic neuropathy resembles
that of Cbl deﬁciency, the role of diabetes in functional Cbl deﬁciency was explored.
RESEARCH DESIGN AND METHODS—A retrospective review was performed of all
ambulatory community-dwelling adults with normal renal function evaluated for Cbl deﬁciency
over a 12-year period in a primary care setting. Functional Cbl deﬁciency was deﬁned as MMA
values .250 nmol/L with Cbl levels .400 pg/mL.
RESULTS—In nondiabetic subjects, MMA values varied directly with age and inversely with
serum Cbl. In diabetic subjects, MMA values also increased with age but did not fall as Cbl levels
increased. Thus, when Cbl levels were .400 pg/mL, mean MMA values and the incidence
of functional Cbl deﬁciency were both signiﬁcantly greater in elderly diabetic subjects (at least
70 years old) than in elderly nondiabetic subjects. Moreover, neuropathy was present in 62%
of diabetic subjects with high MMA values and in only 18% of diabetic subjects with normal
MMA values. Finally, pharmacologic doses of Cbl improved MMA values and neuropathy in
88 and 86% of evaluable diabetic subjects, respectively.
CONCLUSIONS—These observations suggest that functional Cbl deﬁciency is common in
elderly diabetic individuals, is associated with neuropathy, and is responsive to Cbl therapy. A
role for oxidative stress in the pathogenesis of functional Cbl deﬁciency is proposed.
Diabetes Care 34:1077–1080, 2011
C
obalamin (Cbl) deﬁciency is com-
mon in elderly subjects who may
have nonspeciﬁcn e u r o l o g i cc o m -
plaints or appear clinically normal (1).
Elevated levels of the Cbl-dependent
metabolites, methylmalonic acid (MMA)
and total homocysteine (tHcy), in asymp-
tomatic patients with low or low-normal
serum Cbl levels have been termed “sub-
tle” or “preclinical” Cbl deﬁciency, sug-
gesting a continuum of Cbl depletion
beginning with decreased vitamin stores
leading then to metabolite accumulation
and, ﬁnally, to clinical disease (2). How-
ever, 7–30% of diverse elderly popula-
tions have “functional” Cbl deﬁciency,
deﬁned by elevated metabolite values de-
spite Cbl levels well within the normal
reference range, and this disorder has
been linked to decreased cognitive func-
tion, anemia, and neuropathy (3–9).
Functional Cbl deﬁciency might also
result from a disorder common in the
elderly. Diabetes is a particularly attrac-
tive candidate in this regard because it is
associated with sensory and autonomic
neuropathies similar to those seen in Cbl
deﬁciency. Moreover, increased tHcy
levels have been linked to diabetic neu-
ropathy, and pharmacologic doses of Cbl
alone or combined with other vitamins
may improve peripheral and autonomic
nervefunction indiabetichumans(3,10).
Morerecently,a10-yearretrospective
review of symptomatic ambulatory sub-
jects evaluated for Cbl deﬁciency found
9 of the 30 patients who had neurologic
improvement with Cbl therapy had
diabetes (30%) and 8 of these 9 individ-
uals (88%) had functional Cbl deﬁciency
(11). Thus, the roles of diabetes and pa-
tient age in functional Cbl deﬁciency
w e r ee v a l u a t e di nt h et o t a lp o p u l a t i o n
(both symptomatic and asymptomatic)
screened during this period and in the
2 years following.
RESEARCH DESIGN AND
METHODS
Laboratory methods
Because tHcy levels increase in many
settings,MMAwasusedasamorespeciﬁc
index of Cbl deﬁciency (3). Serum Cbl
and MMA were measured as previously
described (normal reference ranges:
200–1,100 pg/mL and 90–250 nmol/L,
respectively) (11). When MMA and Cbl
were measured on more than one occa-
sion within a 4-week period without a
change in treatment, the average values
wereusedforanalysis.FunctionalCblde-
ﬁciency was deﬁned asMMA levels.250
nmol/L when serum Cbl values were
.400 pg/mL.
Patients
A retrospective review of the medical
records of all ambulatory community-
dwelling patients evaluated for Cbl de-
ﬁciency between 1 August 1993 and 30
June 2005 was conducted as previously
described (11). In a preliminary analysis
of nondiabetic subjects with Cbl values
.400 pg/mL, the geometric mean MMA
value in subjects aged ,60 years (173
pg/mL) was similar to that in those aged
60–69 years (187 pg/mL) but was signif-
icantly lower than that in subjects at least
70 years old (225 pg/mL; P , 0.002).
Thus, subjects were divided into those
aged,70yearsandthoseatleast70years
old.BecauseMMAvaluesincreaseinrenal
insufﬁciency, individuals with serum cre-
atininevalues.1.4mg/dLwereexcluded
from analysis (3). For a brief period, nor-
mal MMA values were reported as “less
than 400 nmol/L” and these patients
werealso excluded fromanalysis(n=19).
Concurrent Cbl and MMA values
were obtained in 370 individuals on 432
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ORIGINAL ARTICLEoccasions, including 47 individuals with
type2diabetesevaluatedon59occasions.
Fifty-four patients who were not receiv-
ing Cbl therapy were evaluated on more
than one occasion at least 1 year apart.
Patients were considered to have diabetes
if they were receiving treatment with hy-
poglycemic agents or if they had a fasting
blood glucose level .125 mg/dL or an
HbA1c level .6.4%.
Treatments of diabetic patients in-
cluded diet alone in 14 (30%), insulin in
11 (23%), a sulfonylurea in 15 (32%), a
thiazolidinedione in 4 (9%), and metfor-
minin9(19%),withmorethanoneagent
used in 6 subjects (13%). This study
conforms to the principles of the Decla-
ration of Helsinki of 1975 as revised in
2008, and the institutional human inves-
tigation committee determined that fur-
ther review was not required.
Cbl treatment
Patients were treated with cyanocobala-
min 2 mg/day orally or 1 mg i.m. three
times a week for 2 weeks, weekly for
8 weeks, and monthly thereafter, and
were reevaluated within 1 to 3 months.
Based on the intraindividual variability of
metabolite levels in this population, de-
creases of MMA were considered signiﬁ-
cantiftheywere.116nmol/L(i.e.,.1SD
above the mean intraindividual variability
of MMA) or between 64 and 116 nmol/L
(i.e., between the mean and 1 SD above
the mean intraindividual variability of
MMA) to a value of ,251 nmol/L (11).
Neurologic improvement was considered
to be signiﬁcant if paresthesias completely
resolved, observed ataxic gait became
normal, and/or vibratory sensation that was
completely absent at least in the ankles
before therapy became easily detectable
within 6 months of treatment.
Statistical methods
Population studies suggest skewed distri-
butions for Cbl, MMA, and creatinine
(12). Thus, geometric means, two-tailed
Student t tests using log-transformed
data, x
2 values, and Spearman correla-
tion coefﬁcients were determined using
StatPlus:mac 5.7 software (AnalystSoft,
Vancouver, BC, Canada).
RESULTS
Effects of age and diabetes status
on MMA values
Older individuals with Cbl values .400
pg/mL had mean MMA values that were
51 and 26% higher than their younger
counterparts in diabetic and nondiabetic
populations, respectively (Table 1). The
incidence of functional Cbl deﬁciency
was also greater in older than in younger
individuals within the diabetic (8 of 11
[73%] vs. 6 of 17 subjects [35%]) and
nondiabetic (19 of 47 [40%] vs. 17 of
73 subjects [23%]) populations (P #
0.05).
Diabetic subjects with Cbl levels
.400 pg/mL had higher mean MMA
values than nondiabetic subjects in both
age-groups, and this difference was statis-
tically signiﬁcant in the older population
(Table 1). However, mean values for Cbl
and creatinine were not signiﬁcantly dif-
ferent in diabetic and nondiabetic sub-
jects of comparable age. Functional Cbl
deﬁciency was present in 8 of 11 older
diabetic subjects (73%) compared with
19 of 47 older nondiabetic subjects
(40%; P , 0.05).
Determinants of MMA in diabetic
and nondiabetic subjects
A g ew a sas i g n i ﬁcant determinant of
MMA in both diabetic and nondiabetic
populations (Table 2). The relationship
between age and MMA was particularly
strong when Cbl levels exceeded 400
pg/mL (diabetes: r = +0.52, P , 0.006,
n = 28; nondiabetes: r = +0.30, P , 0.001,
n = 120). Cbl was a signiﬁcant determinant
of MMA only in nondiabetic subjects, but
creatinine was not a signiﬁcant determinant
of MMA in either population.
Effect of Cbl therapy on MMA values
MMA responses to Cbl therapy were
evaluable in 24 of 29 diabetic patients
(83%) and in 110 of 173 nondiabetic
patients (64%) with MMA values .250
nmol/L. Of these 134 patients, 77 re-
ceived parenteral therapy (57%). Meta-
bolic responses to Cbl therapy occurred
in 115 of 134 patients (86%) overall
(Table 3). MMA values fell into the nor-
mal range in 110 patients (81%). The re-
sponse rate was not affected by diabetes
status, patient age, or serum Cbl level
(Table 3).
An additional eight diabetic subjects
with renal insufﬁciency and high MMA
values, despite normal serum Cbl levels,
received Cbl therapy, including seven
with creatinine values of 1.7 to 2.3 mg/dL
and one individual receiving chronic
hemodialysis with a creatinine value of
9.4 mg/dL. MMA values decreased signif-
icantlyinﬁvepatients(63%)andreturned
to a normal value in three (38%; data not
shown).
Neuropathy in diabetic subjects and
the effects of Cbl therapy
Of the 47 diabetic subjects, 17 had no
neurologic ﬁndings, 15 had neuropathy
Table 1—Effect of diabetes status relative to patient age on mean MMA values
in subjects with Cbl levels >400 pg/mL
Variable
Age ,70 years Age at least 70 years
Diabetic Nondiabetic
P
Diabetic Nondiabetic
P n =1 7 n =7 3 n =1 1 n =4 7
MMA (nmol/L) 209 178 NS 315* 225† 0.03
Creatinine (mg/dL) 1.0 0.9 NS 1.1 1.0 NS
Cbl (pg/mL) 537 563 NS 622 648 NS
Age (years) 54 48 NS 76 77 NS
Values are geometric means for the number of subjects, and P values compare individuals with and without
diabetes in the same age-group. NS, not signiﬁcant. *P , 0.05 compared with diabetic subjects aged ,70
years. †P , 0.0025 compared with nondiabetic subjects aged ,70 years.
Table 2—Determinants of MMA in diabetic and nondiabetic populations
Determinant
Diabetic (n = 57)* Nondiabetic (n = 369)†
rP r P
Cbl (pg/mL) +0.03 NS 20.31 ,0.001
Age (years) +0.38 ,0.005 +0.15 ,0.005
Creatinine (mg/dL) +0.07 NS +0.08 NS
Spearman correlation coefﬁcients were determined as described in the RESEARCH DESIGN AND METHODS. *Omits
two diabetes outliers with MMA values of 1,309 and 1,829 nmol/L. †Omits four nondiabetic outliers with
MMA values of 1,319, 3,279, 1,928, and 4,911 nmol/L.
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Diabetes and functional cobalamin deﬁciencythat was unexplained except for the pres-
ence of diabetes, and 15 had neuropathy
that was possibly multifactorial. When
the latter group was excluded from anal-
y s i s ,2 1o ft h er e m a i n i n g3 2p a t i e n t sh a d
high MMA values (63%), and 13 of these
patients had neuropathy (62%). In con-
trast, only 2 of the 11 patients (18%) with
normal MMA values had neurologic signs
or symptoms (P , 0.02).
At least 3 months of Cbl treatment
was given to 14 diabetic subjects with
neuropathy and increased MMA values,
and signiﬁcant responses were noted in 9
of 10 subjects (90%) with otherwise un-
explainedneuropathyand in3of4(75%)
with multifactorial neuropathy, for an
overall response rate of 86% (Table 4).
Pretreatment Cbl levels were within the
normal range in all 14 subjects and were
.400 pg/mL in 9 subjects, including 8 of
the 12 responders (75%). One evaluable
subject with neuropathy received metfor-
min (patient 13, Table 4).
CONCLUSIONS—Despite associa-
tions of high tHCy values with diabetic
neuropathy and reports of clinical re-
sponses of diabetic neuropathy to Cbl
therapy, the role of diabetes as a possible
cause of functional Cbl deﬁciency has
not been evaluated (3,13). Indeed, only
three studies have reported MMA values
in diabetic subjects, and these were lim-
itedbythelack ofan age-matched control
group, the presence of renal failure, or a
focus on frank diet-related Cbl deﬁciency
(3,13).
The current study conﬁrms the asso-
ciation between age and functional Cbl
deﬁciency in nondiabetic subjects and
extends this observation to the diabetic
population (Tables 1 and 2). Moreover,
elderly diabetic patients with Cbl values
.400 pg/mL had higher mean MMA
values than both younger diabetic indi-
viduals and elderly nondiabetic individ-
uals, suggesting an additive effect of
diabetesandageontheriskoffunctional
Cbl deﬁciency (Table 1). Differences
b e t w e e ni n d i v i d u a l sw i t ha n dw i t h o u t
diabetes were not explained by differen-
ces in Cbl, age, or creatinine level, and
pharmacologic doses of Cbl consistently
decreased MMA values in all groups
(Tables 1 and 3).
The clinical signiﬁcance of functional
Cbl deﬁciency is controversial. Associa-
tions with cognitive dysfunction, anemia,
and neuropathy have been reported, and
clinical responses to Cbl therapy have
been noted (3,6,11,14). In contrast, clin-
ical responses were not seen in six thera-
peutic trials (3,15–17). The current study
indeed suggests that functional Cbl deﬁ-
ciencyindiabeticsubjects isclinicallysig-
niﬁcant because neuropathy was more
common when MMA values were high,
and Cbl therapy improved neuropathy
in 86% of evaluable patients (Table 4).
Similar neurologic responses to Cbl ther-
apy in diabetic subjects have been previ-
ously reported, but measures of Cbl and
MMA were not obtained (3,10).
The mechanism of functional Cbl
deﬁciency in diabetes and aging is un-
known. Interestingly, functional Cbl de-
ﬁciency in some inborn errors of Cbl
metabolism results from the impaired
reduction of Cbl from the Co
III transport
form to the active Co
I or Co
II coenzyme
states, and correction of metabolic and
clinical abnormalities in these disorders
requires extremely high doses of paren-
teralCbl(18).Moreover,Cblisparticularly
susceptible to oxidation, and enzymatic
reduction is also required for the de-
cyanation of therapeutic cyanoCo
IIICbl
(19–21).
Because aging and diabetes are both
associatedwithincreasedoxidativestress,
a role for oxidative stress in the pathogen-
esis of functional Cbl deﬁciency and for
the requirement of pharmacologic doses
of Cbl in this setting is proposed (Fig. 1)
(22–24). This hypothesis also implies
that treatment with a reduced form of
Cbl (e.g., methylcobalamin) may have
an advantage over the oxidized forms of
Cbl that are usually administered (i.e.,
cyanocobalamin and hydroxycobala-
min). Indeed, high doses of methylcoba-
lamin have been reported to improve
diabetic neuropathy, but the relationship
of these responses to functional Cbl de-
ﬁciency has not been studied (3,25).
Table 3—Metabolic responses to Cbl therapy in patients with elevated MMA values
Cbl
Age ,70 years Age at least 70 years All ages
Diabetic Nondiabetic Diabetic Nondiabetic Diabetic Nondiabetic
,401 pg/mL 8/8 (100) 51/57 (89) 3/3 (100) 26/30 (87) 11/11 (100) 77/87 (89)
.400 pg/mL 4/6 (67) 10/14 (71) 6/7 (86) 7/9 (86) 10/13 (77) 17/23 (74)
All 12/14 (86) 61/71 (86) 9/10 (90) 33/39 (85) 21/24 (88) 94/110 (85)
Dataarepresentedasn(%).Responsestotreatmentwithcyanocobalaminareasdeﬁnedinthe RESEARCHDESIGN
AND METHODS.
Table 4—Neurologic responses to Cbl therapy in diabetic subjects with high MMA values
Patient Age Sex Cbl
MMA Neurologic responses
Pre-Rx Post-Rx Any Paresthesias Ataxic gait Vibration sense
1 71 F 916 306 222 Yes* Resolves ND Returns†
2 68 M 706 318 199 Yes‡ Resolves ND Returns†
3 77 M 468 282 166 Yes§ Resolves ND ND
4 72 M 370 296 143 Yes Resolves ND ND
5 82 M 422 360 253 Yes* NA ND Returns†
6 65 F 444 406 313 Yes Resolves ND Returns†
7 59 F 377 353 89 Yes‡ Resolves Resolves ND
8 56 F 587 277 179 Yes Resolves Improves NA
9 58 F 322 354 126 Yes NA Resolves Normal
10 53 M 800 342 189 No No change No change ND
11 53 F 406 265 178 Yes NA Improves Returns†
12 76 M 721 251 ND Yes Improves Improves Returns†
13 68 M 322 269 200 Yes Resolves ND Returns†
14 53 M 400 450 200 No No change No change ND
Diabetes was the only apparent cause for neuropathy in patients 1–10, whereas other causes for neuropathy
were present in patients 11–14. Patients 8 and 13 were treated with cyanocobalamin orally, and the other 12
subjects received intramuscular cyanocobalamin as described in the RESEARCH DESIGN AND METHODS.F ,f e m a l e ;
M, male; NA, not applicable because of normal pretherapy ﬁndings; ND, not tested; Rx, pharmacologic
therapy. *Orthostatic hypotension also resolved.†Vibration sensation returnedto the anklesin patients2, 6,
12,and 13; to both thekneesandankles in patients5,7, and11; andto thehips, knees,and anklesin patient
1. ‡Restless legs also resolved. §Light touch sensation also returned to the legs.
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SolomonThis study is the ﬁrst to report MMA
values in diabetic subjects with normal
Cbl levels and provide information on
the Cbl responsiveness of neuropathy
in relation to the presence of functional
Cbl deﬁciency. Future studies of larger
numbers of subjects with randomized,
placebo-controlled trials of Cbl therapy
are required to conﬁrm and extend these
observations.
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